Moleculin Biotech
MBRX
15 hedge funds and large institutions have $519K invested in Moleculin Biotech in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 5 closing their positions.
52% more capital inflows, than outflows
Capital inflows: $322K | Capital outflows: $211K
0.63% more ownership
Funds ownership: 2.85% → 3.48% (+0.63%)
0% more funds holding
Funds holding: 15 → 15 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$72.4K |
| 2 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$60.8K |
| 3 |
XTX Topco
George Town,
Cayman Islands
|
+$58.6K |
| 4 |
Morgan Stanley
New York
|
+$51.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$38.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$172K |
| 2 |
HRT Financial
New York
|
-$31K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7.81K |
| 4 |
Pinnacle Wealth Planning Services
Mansfield,
Ohio
|
-$643 |
| 5 |
Vanguard Global Advisers
Malvern,
Pennsylvania
|
-$55 |
MBRX Hedge Fund Activity: Q2 2026 in Review
15 of the 8,372 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2026, worth a combined $519K — up 49% from $348K a quarter earlier.
Fund positioning in MBRX was balanced in Q2 2026: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Capital Management, adding an estimated $72.4K. The largest seller was Sabby Management, exiting entirely with an estimated $172K sold.
- 15 institutional investors held Moleculin Biotech (MBRX) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $519K of Moleculin Biotech stock for Q2 2026, up 49% quarter-over-quarter.
- 5 funds opened new Moleculin Biotech positions in Q2 2026 and 5 closed out, a net change of 0 holders.
- The largest Moleculin Biotech buyer in Q2 2026 was Vanguard Capital Management, an estimated $72.4K added.
- The largest Moleculin Biotech seller in Q2 2026 was Sabby Management, an estimated $172K sold.
Based on aggregated 13F filings for Q2 2026.